But Lucentis has to be injected into the eye every month or two, a burden for patients and doctors.
使用Lucentis治疗需要每一两个月进行眼部注射，无论对患者还是医生来说，都是一个沉重负担。
But an unusual conflict of interest means that Genentech, the drug company that produces Lucentis, is conspicuously silent.
但是一个不同寻常的利益冲突意味着制药公司基因泰克对此格外地沉默。
Medicare could save hundreds of millions of dollars a year if everyone used the cheaper drug, Avastin, instead of the costlier one, Lucentis.
如果每个人都使用更便宜的药物安维汀，而不是更昂贵的雷珠单抗，那么医疗保障每年就可以节省数亿美元。
A drug called Lucentis, made by Genetech, has proved effective at treating the wet form of age-related macular degeneration, which can lead to blindness.
Genetech公司研制的药物Lucentis被证明能够有效治疗湿性年龄相关性黄斑变性(亦称老年性黄斑变性)，这种眼病可以导致失明。
The Food and Drug Administration has not approved Avastin for use in the eye, and using it rather than the alternative, Lucentis, might carry an additional, although slight, safety risk.
美国食品和药品管理局还没有批准阿瓦斯汀用于眼部治疗，使用它来代替雷珠单抗可能会产生额外的安全风险，尽管这一风险也许很轻微。
The Food and Drug Administration has not approved Avastin for use in the eye, and using it rather than the alternative, Lucentis, might carry an additional, although slight, safety risk.
美国食品和药品管理局还没有批准阿瓦斯汀用于眼部治疗，使用它来代替雷珠单抗可能会产生额外的安全风险，尽管这一风险也许很轻微。
应用推荐